查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2019269

全球鼻腔给药装置市场：依药物类型、装置类型、最终用户、应用及地区划分－市场规模、市场动态、机会分析及2026-2035年预测

Global Nasal Mucosa Drug Supply Device Market: By Drug Type, Device Type, End-User, Application, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

鼻腔给药装置市场正经历快速扩张，反映出人们对非侵入性高效给药方式日益增长的需求。预计2025年市场规模将达到93.6亿美元，未来十年将成长近一倍，2035年达到约202.1亿美元。这一显着成长意味着8.0%的强劲复合年增长率，凸显了鼻腔给药技术在各个医疗领域日益普及和广泛接受。

推动该市场快速成长的主要因素之一是对快速、无针全身给药方式的需求日益增长。患者和医护人员都在寻求传统注射和口服药物的替代方案，他们更倾向于使用起效更快、患者舒适度更高的鼻腔给药装置。对于那些害怕针头或需要快速起效的患者（例如在紧急情况下），这种转变尤其重要。

显着的市场趋势

鼻腔给药装置市场呈现典型的寡占格局，少数主要企业主导市场，合计控制约70%的OEM（目的地设备製造商）产量。引领这一竞争格局的是AptarGroup、Nemera、Becton Dickinson (BD) 和Teleflex，它们各自凭藉着无可比拟的规模、强大的知识产权组合和深厚的监管专业知识，维持着稳固的市场地位。

AptarGroup是该领域销量领先的公司，拥有超过100项与多剂量和单剂量给药系统相关的专利。其技术是其畅销急救吸入器的核心，该产品年销售额超过2亿美元。同时，Nemera专注于无防腐剂帮浦系统，开闢了一个利润丰厚的细分市场。该公司对严格遵守良好生产规范 (GMP) 和精确剂量控制的承诺，使其在欧洲市场占据了25%的领先份额。

贝克顿·迪金森公司 (BD) 正利用其 Accuspray 平台支持大规模疫苗接种活动，鑑于全球对免疫计划的重视，这是一个至关重要的成长领域。 BD 从中受益匪浅，其获得 FDA核准的复合食品药物管理局相关合约的特许权使用费约为 1 亿美元。

关键成长要素

居家照护和自我给药方式的转变是鼻粘膜给药装置市场成长的关键驱动因素。自新冠疫情爆发以来，宏观经济领域出现了一系列旨在减轻医院和临床机构负担的措施。这项转变源自于减轻医院负担、优化资源配置并最终降低医疗成本的需求。患者和医疗服务提供者都越来越倾向于采用能够在传统临床环境之外进行有效治疗的解决方案。

新机会的趋势

干粉製剂的创新在推动鼻腔给药装置在市场上的广泛应用方面发挥了至关重要的作用。这些先进的给药系统彻底改变了鼻内给药方式，为传统的液体喷雾剂提供了更高效的替代方案。透过使用冷冻干燥粉末，这些装置能够以干燥形式精准稳定地输送药物，从而延长热敏性药物的保质期并提高其稳定性。

优化障碍

製剂方面的限制是鼻黏膜给药装置市场成长面临的一大挑战。其中一个主要障碍是难以有效地将胜肽类和蛋白质等高分子量化合物经由鼻腔递送。这些大分子药物通常面临吸收和生物利用度方面的障碍，难以在标靶达到治疗浓度。这种限制缩小了可用于鼻腔给药的药物范围，进而限制了某些先进治疗方法的市场潜力。

目录

第一章执行摘要：全球鼻腔给药装置市场

第二章：调查方法与研究框架

  • 研究目标
  • 产品概述
  • 市场区隔
  • 定性研究
    • 一手和二手资讯
  • 量化研究
    • 一手和二手资讯
  • 按地区分類的主要调查受访者组成
  • 本研究的前提
  • 市场规模估算
  • 数据检验

第三章：全球鼻粘膜给药装置市场概述

  • 产业价值链分析
    • 原物料供应商
    • 设备製造商
    • 分销管道
    • 最终用户
  • 产业展望
    • 鼻腔给药技术进展
    • 监理形势与核准框架
    • 产品核准及研发管线分析
    • 世界贸易分析
    • 主要买家和供应商
  • PESTLE分析
  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场成长及前景
    • 市场收入估算与预测（2020-2035 年）
    • 2020-2035年市场规模估算与预测（单位：百万）
    • 价格趋势分析

第四章：鼻粘膜给药装置的全球市场分析

  • 竞争格局概述
    • 市场集中度
    • 企业市场占有率分析（以金额为准，%），2025 年
    • 竞争对手分析与基准测试

第五章：鼻粘膜给药装置的全球市场分析

  • 市场动态和趋势
    • 成长要素
    • 抑制因子
    • 机会
    • 主要趋势
  • 市场规模及预测（2020-2035）
    • 依药物类型
      • 主要分析结果
        • 呼吸系统药物
        • 止痛药
        • 疫苗
        • 神经系统药物
        • 荷尔蒙疗法药物
        • 急救
    • 透过使用
      • 主要分析结果
        • 过敏性鼻炎
        • 鼻窦炎和鼻塞
        • 偏头痛
        • 其他的
    • 最终用户
      • 主要分析结果
        • 医院和诊所
        • 居家医疗
        • 药局
        • 其他的
    • 按地区
      • 主要分析结果
        • 北美洲
          • 我们
          • 加拿大
          • 墨西哥
        • 欧洲
          • 西欧
            • 英格兰
            • 德国
            • 法国
            • 义大利
            • 西班牙
            • 其他西欧国家
          • 东欧
            • 波兰
            • 俄罗斯
            • 其他东欧国家
        • 亚太地区
          • 中国
          • 印度
          • 日本
          • 韩国
          • 澳洲和纽西兰
          • ASEAN
            • 印尼
            • 马来西亚
            • 泰国
            • 新加坡
            • 其他东协国家
          • 其他亚太地区
        • 中东和非洲
          • 阿拉伯聯合大公国
          • 沙乌地阿拉伯
          • 南非
          • 其他中东和非洲地区
        • 南美洲
          • 阿根廷
          • 巴西
          • 南美洲其他地区

第六章：北美市场分析

第七章：欧洲市场分析

第八章：亚太地区市场分析

第九章：中东和非洲市场分析

第十章：南美市场分析

第十一章：公司简介

  • AptarGroup
  • Becton Dickinson and Company
  • GlaxoSmithKline
  • Johnson &Johnson
  • Merck &Co.
  • Novartis
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries
  • Other Prominent Players

第十二章附录

简介目录
Product Code: AA03261725

The nasal mucosa drug supply device market is experiencing rapid expansion, reflecting a growing preference for non-invasive and efficient drug delivery methods. Starting from an estimated baseline value of USD 9.36 billion in 2025, the market is projected to nearly double over the next decade, reaching approximately USD 20.21 billion by 2035. This impressive growth represents a robust compound annual growth rate (CAGR) of 8.0%, underscoring the increasing adoption and acceptance of nasal drug delivery technologies across various healthcare sectors.

One of the primary drivers behind this market surge is the rising demand for systemic drug delivery methods that are both rapid and needle-free. Patients and healthcare providers alike are seeking alternatives to traditional injections and oral medications, favoring nasal devices that offer faster onset of action and improved patient comfort. This shift is particularly important for individuals with needle phobia or those requiring quick therapeutic effects, such as in emergency situations.

Noteworthy Market Developments

The nasal mucosa drug supply device market operates as a classic oligopoly, dominated by a small group of key players that collectively control about 70% of original equipment manufacturer (OEM) production. Leading this competitive landscape are AptarGroup, Nemera, Becton Dickinson (BD), and Teleflex, each leveraging their unmatched scale, robust intellectual property portfolios, and deep regulatory expertise to maintain its powerful market positions.

AptarGroup stands out as the revenue leader in this sector, boasting over 100 patents related to both multi-dose and unit-dose delivery systems. Their technologies are integral to blockbuster rescue inhalers, generating more than $200 million in annual sales. Nemera, meanwhile, has carved out high-margin niches by focusing on preservative-free pump systems. Their commitment to good manufacturing practice (GMP) excellence and precision dosing has earned them a commanding 25% share of the European market.

Becton Dickinson (BD) leverages its Accuspray platforms to support large-scale vaccine deployments, a critical area of growth given the global emphasis on immunization programs. BD benefits from substantial royalty income, generating around $100 million from combination-device agreements following approvals by the U.S. Food and Drug Administration (FDA).

Core Growth Drivers

The shift towards at-home care and self-administration has become a significant driver of growth in the nasal mucosa drug supply device market. Since the COVID-19 pandemic, there has been a broad macroeconomic movement aimed at reducing the strain on hospitals and clinical settings. This shift is motivated by the need to alleviate hospital burdens, optimize resource allocation, and ultimately reduce healthcare costs. Patients and healthcare providers alike are increasingly embracing solutions that enable effective treatment outside traditional clinical environments.

Emerging Opportunity Trends

Innovations in dry-powder devices are playing a crucial role in driving the adoption of nasal mucosa drug supply devices within the market. These advanced delivery systems have transformed the way medications are administered nasally by offering a sophisticated alternative to traditional liquid sprays. By utilizing lyophilized powders, these devices enable the precise and stable delivery of drugs in a dry form, which can enhance the shelf life and stability of sensitive pharmaceutical compounds.

Barriers to Optimization

Formulation limitations present a significant challenge that could hamper the growth of the nasal mucosa drug supply device market. One of the primary obstacles lies in the difficulty of effectively delivering high molecular weight compounds, such as peptides and proteins, through the nasal route. These large molecules often face barriers related to absorption and bioavailability, making it challenging to achieve therapeutic concentrations in the target area. This limitation restricts the range of drugs that can be formulated for nasal delivery, thereby narrowing the market potential for certain advanced therapies.

Detailed Market Segmentation

By device type, metered-dose spray systems (MDSS) held a dominant position in the nasal mucosa drug supply device market, accounting for 44.85% of the global revenue in 2025. This leadership is largely attributed to the unparalleled precision these systems offer in delivering exact doses of medication, which is essential for both patient safety and therapeutic efficacy. The ability of MDSS to consistently administer controlled amounts of drugs makes them highly favored by pharmaceutical engineers who prioritize accuracy in drug formulation and delivery.

By application, allergic rhinitis accounts for a significant portion of the market revenue, capturing approximately 41.18%. This impressive share is driven by the large epidemiological prevalence of the condition as well as the pharmacokinetic advantages offered by treatments targeting it. Allergic rhinitis forms the volume backbone of the market, even though central nervous system (CNS) devices tend to generate higher profit margins. The widespread occurrence of allergic rhinitis ensures consistent demand, making it a critical focus area within nasal drug delivery applications.

By end users, hospitals and clinics dominate the nasal mucosa drug supply device market, holding a significant 56% share. This strong position is maintained through the securing of high-value contracts, reflecting the critical role these healthcare facilities play despite an increasing trend toward home-care solutions. The preference for hospitals and clinics is largely due to the irreplaceable nature of acute and supervised medical treatments that require precise and immediate drug delivery.

Segment Breakdown

By Device Type

  • Metered-Dose Spray Systems
  • Breath-Actuated Systems
  • Multi-Dose Dispensers
  • Nebulizers & Atomizers
  • Powder-Based Delivery Systems
  • Others

By Drug Type

  • Respiratory Drugs
  • Pain Management Drugs
  • Vaccines
  • Neurological Drugs
  • Hormone Therapies
  • Emergency Drugs

By Application

  • Allergic Rhinitis
  • Sinusitis & Nasal Congestion
  • Migraine
  • Others

By End-User

  • Hospitals & Clinics
  • Home Care
  • Retail Pharmacies
  • Others

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America stands as the undisputed leader in the global market, commanding an estimated 45.8% share of the total market landscape. This dominant position is the result of several interrelated factors that have shaped the region's unique market dynamics and growth trajectory. Central to this leadership is the high adoption of biologics and drug-device combination products, which benefit from a healthcare system that supports premium pricing models. These pricing structures allow manufacturers to justify the often substantial research and development costs associated with innovative technologies such as novel mucosal atomizers.
  • Another significant driver of North America's market dominance is the ongoing opioid epidemic, a public health crisis that has necessitated widespread deployment of rescue therapeutics at the community level. In response to this tragic epidemic, millions of unit-dose intranasal naloxone devices-such as Narcan-are distributed annually across first responders, educational institutions, and private homes. This large-scale distribution has dramatically increased the regional market volume for intranasal delivery devices, creating a robust demand that far exceeds that of many other regions.
  • Furthermore, the presence of a mature regulatory infrastructure specifically designed to address the complexities of combination products has played a pivotal role in fostering domestic biopharmaceutical investment. This regulatory environment offers clear guidelines and pathways for approval, reducing uncertainty and facilitating faster development timelines for intranasal drug-device products.

Leading Market Participants

  • AptarGroup
  • Becton Dickinson and Company
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical Industries
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Nasal Mucosa Drug Supply Device Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Nasal Mucosa Drug Supply Device Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers
    • 3.1.2. Device Manufacturers
    • 3.1.3. Distribution Channels
    • 3.1.4. End Users
  • 3.2. Industry Outlook
    • 3.2.1. Technological Advancements in Nasal Drug Delivery
    • 3.2.2. Regulatory Landscape & Approval Framework
    • 3.2.3. Product Approvals & Pipeline Analysis
    • 3.2.4. Global Trade Analysis
    • 3.2.5. Key Buyers & Suppliers
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Market Volume Estimates and Forecast (Mn Units), 2020-2035
    • 3.5.3. Price Trend Analysis

Chapter 4. Global Nasal Mucosa Drug Supply Device Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Nasal Mucosa Drug Supply Device Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 5.2.1. By Drug Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Respiratory Drugs
        • 5.2.1.1.2. Pain Management Drugs
        • 5.2.1.1.3. Vaccines
        • 5.2.1.1.4. Neurological Drugs
        • 5.2.1.1.5. Hormone Therapies
        • 5.2.1.1.6. Emergency Drugs
    • 5.2.2. By Application
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Allergic Rhinitis
        • 5.2.2.1.2. Sinusitis & Nasal Congestion
        • 5.2.2.1.3. Migraine
        • 5.2.2.1.4. Others
    • 5.2.3. By End-User
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Hospitals & Clinics
        • 5.2.3.1.2. Home Care
        • 5.2.3.1.3. Retail Pharmacies
        • 5.2.3.1.4. Others
    • 5.2.4. By Region
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. North America
          • 5.2.4.1.1.1. The U.S.
          • 5.2.4.1.1.2. Canada
          • 5.2.4.1.1.3. Mexico
        • 5.2.4.1.2. Europe
          • 5.2.4.1.2.1. Western Europe
            • 5.2.4.1.2.1.1. The UK
            • 5.2.4.1.2.1.2. Germany
            • 5.2.4.1.2.1.3. France
            • 5.2.4.1.2.1.4. Italy
            • 5.2.4.1.2.1.5. Spain
            • 5.2.4.1.2.1.6. Rest of Western Europe
          • 5.2.4.1.2.2. Eastern Europe
            • 5.2.4.1.2.2.1. Poland
            • 5.2.4.1.2.2.2. Russia
            • 5.2.4.1.2.2.3. Rest of Eastern Europe
        • 5.2.4.1.3. Asia Pacific
          • 5.2.4.1.3.1. China
          • 5.2.4.1.3.2. India
          • 5.2.4.1.3.3. Japan
          • 5.2.4.1.3.4. South Korea
          • 5.2.4.1.3.5. Australia & New Zealand
          • 5.2.4.1.3.6. ASEAN
            • 5.2.4.1.3.6.1. Indonesia
            • 5.2.4.1.3.6.2. Malaysia
            • 5.2.4.1.3.6.3. Thailand
            • 5.2.4.1.3.6.4. Singapore
            • 5.2.4.1.3.6.5. Rest of ASEAN
          • 5.2.4.1.3.7. Rest of Asia Pacific
        • 5.2.4.1.4. Middle East & Africa
          • 5.2.4.1.4.1. UAE
          • 5.2.4.1.4.2. Saudi Arabia
          • 5.2.4.1.4.3. South Africa
          • 5.2.4.1.4.4. Rest of MEA
        • 5.2.4.1.5. South America
          • 5.2.4.1.5.1. Argentina
          • 5.2.4.1.5.2. Brazil
          • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Drug Type
      • 6.2.1.2. By Application
      • 6.2.1.3. By End-User
      • 6.2.1.4. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Drug Type
      • 7.2.1.2. By Application
      • 7.2.1.3. By End-User
      • 7.2.1.4. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Drug Type
      • 8.2.1.2. By Application
      • 8.2.1.3. By End-User
      • 8.2.1.4. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Drug Type
      • 9.2.1.2. By Application
      • 9.2.1.3. By End-User
      • 9.2.1.4. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn & Mn Units)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Drug Type
      • 10.2.1.2. By Application
      • 10.2.1.3. By End-User
      • 10.2.1.4. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. AptarGroup
  • 11.2. Becton Dickinson and Company
  • 11.3. GlaxoSmithKline
  • 11.4. Johnson & Johnson
  • 11.5. Merck & Co.
  • 11.6. Novartis
  • 11.7. Pfizer
  • 11.8. Sanofi
  • 11.9. Teva Pharmaceutical Industries
  • 11.10. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators